Publication | Open Access

Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus

MedicineType 2Mechanism Of ActionPharmacological AgentPharmacotherapyDrug DevelopmentPharmacologyDrug Discovery